医学
埃尔特罗姆博帕格
加药
肝性脑病
代谢性酸中毒
脑病
不利影响
儿科
内科学
重症监护医学
胃肠病学
免疫性血小板减少症
肝硬化
血小板
作者
Erin Hermann,Asmaa Ferdjallah
出处
期刊:Journal of Pediatric Hematology Oncology
[Ovid Technologies (Wolters Kluwer)]
日期:2021-08-25
卷期号:44 (2): e453-e455
被引量:5
标识
DOI:10.1097/mph.0000000000002300
摘要
Eltrombopag is approved for the treatment of chronic immune thrombocytopenia purpura (ITP) in pediatric patients 1 year and older who have demonstrated an insufficient response to corticosteroids and intravenous immunoglobulin. We present the case of a 2-year-old boy with chronic immune thrombocytopenia purpura who developed life-threatening adverse effects of acute liver failure, metabolic acidosis and encephalopathy with standard drug dosing. To our knowledge, this is the first case of eltrombopag-induced hepatic encephalopathy highlighting the critical need for prescribers to exercise caution when prescribing eltrombopag in the pediatric setting.
科研通智能强力驱动
Strongly Powered by AbleSci AI